KRYS - Krystal Biotech: Update On KB103 Phase I Patients And Implications For Phase II

Phase I/II Study

In early October, Krystal Biotech (KRYS) reported impressive data from its phase I/II gene therapy trial investigating KB103 as a treatment for dystrophic epidermolysis bulossa ((DEB)), a genetic condition characterized by severe chronic blisters and wounds. A mutation causes patients to lack the production of functional collagen VII, needed to construct anchoring fibrils which hold the inner and outer layers of the skin together. KB103 is a modified HSV-1 virus, administered in an off-the-shelf gel that delivers a functional collagen VII gene to affected wounds. With

Read more ...